These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31931337)

  • 1. Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
    Runfola M; Sestito S; Bellusci L; La Pietra V; D'Amore VM; Kowalik MA; Chiellini G; Gul S; Perra A; Columbano A; Marinelli L; Novellino E; Rapposelli S
    Eur J Med Chem; 2020 Feb; 188():112006. PubMed ID: 31931337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.
    Ye L; Li YL; Mellström K; Mellin C; Bladh LG; Koehler K; Garg N; Garcia Collazo AM; Litten C; Husman B; Persson K; Ljunggren J; Grover G; Sleph PG; George R; Malm J
    J Med Chem; 2003 Apr; 46(9):1580-8. PubMed ID: 12699376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of two novel agonists of thyroid hormone receptor-β on liver regeneration.
    Perra A; Kowalik MA; Cabras L; Runfola M; Sestito S; Migliore C; Giordano S; Chiellini G; Rapposelli S; Columbano A
    Cell Prolif; 2020 May; 53(5):e12808. PubMed ID: 32347601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.
    Kelly MJ; Pietranico-Cole S; Larigan JD; Haynes NE; Reynolds CH; Scott N; Vermeulen J; Dvorozniak M; Conde-Knape K; Huang KS; So SS; Thakkar K; Qian Y; Banner B; Mennona F; Danzi S; Klein I; Taub R; Tilley J
    J Med Chem; 2014 May; 57(10):3912-23. PubMed ID: 24712661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo evaluation of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists: importance of liver selectivity in drug discovery.
    Takahashi N; Asano Y; Maeda K; Watanabe N
    Biol Pharm Bull; 2014; 37(7):1103-8. PubMed ID: 24989002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.
    Shiohara H; Nakamura T; Kikuchi N; Ozawa T; Nagano R; Matsuzawa A; Ohnota H; Miyamoto T; Ichikawa K; Hashizume K
    Bioorg Med Chem; 2012 Jun; 20(11):3622-34. PubMed ID: 22542282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptor β (TRβ) selective agonists.
    Shiohara H; Nakamura T; Kikuchi N; Ozawa T; Matsuzawa A; Nagano R; Ohnota H; Miyamoto T; Ichikawa K; Hashizume K
    Bioorg Med Chem; 2013 Feb; 21(3):592-607. PubMed ID: 23276448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders.
    Saponaro F; Sestito S; Runfola M; Rapposelli S; Chiellini G
    Front Med (Lausanne); 2020; 7():331. PubMed ID: 32733906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist.
    Taub R; Chiang E; Chabot-Blanchet M; Kelly MJ; Reeves RA; Guertin MC; Tardif JC
    Atherosclerosis; 2013 Oct; 230(2):373-80. PubMed ID: 24075770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid Hormone Analogues: An Update.
    Zucchi R
    Thyroid; 2020 Aug; 30(8):1099-1105. PubMed ID: 32098589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).
    Luong XG; Stevens SK; Jekle A; Lin TI; Gupta K; Misner D; Chanda S; Mukherjee S; Williams C; Stoycheva A; Blatt LM; Beigelman LN; Symons JA; Raboisson P; McGowan D; Vandyck K; Deval J
    PLoS One; 2020; 15(12):e0240338. PubMed ID: 33306682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
    Erion MD; Cable EE; Ito BR; Jiang H; Fujitaki JM; Finn PD; Zhang BH; Hou J; Boyer SH; van Poelje PD; Linemeyer DL
    Proc Natl Acad Sci U S A; 2007 Sep; 104(39):15490-5. PubMed ID: 17878314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of the thyroid hormone receptor beta-subtype agonist KB-141: a strategy for body weight reduction and lipid lowering with minimal cardiac side effects.
    Grover GJ; Mellstrom K; Malm J
    Cardiovasc Drug Rev; 2005; 23(2):133-48. PubMed ID: 16007230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac specific effects of thyroid hormone analogues.
    Danzi S; Klein I
    Horm Metab Res; 2011 Oct; 43(11):737-42. PubMed ID: 22009366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia.
    Jakobsson T; Vedin LL; Parini P
    Drugs; 2017 Oct; 77(15):1613-1621. PubMed ID: 28865063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptor β agonists.
    Burkholder TP; Cunningham BE; Clayton JR; Lander PA; Brown ML; Doti RA; Durst GL; Montrose-Rafizadeh C; King C; Osborne HE; Amos RM; Zink RW; Stramm LE; Burris TP; Cardona G; Konkol DL; Reidy C; Christe ME; Genin MJ
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1377-80. PubMed ID: 25752984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes.
    Grover GJ; Mellström K; Malm J
    Curr Vasc Pharmacol; 2007 Apr; 5(2):141-54. PubMed ID: 17430219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats.
    Perra A; Simbula G; Simbula M; Pibiri M; Kowalik MA; Sulas P; Cocco MT; Ledda-Columbano GM; Columbano A
    FASEB J; 2008 Aug; 22(8):2981-9. PubMed ID: 18434432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141.
    Bryzgalova G; Effendic S; Khan A; Rehnmark S; Barbounis P; Boulet J; Dong G; Singh R; Shapses S; Malm J; Webb P; Baxter JD; Grover GJ
    J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):262-7. PubMed ID: 18621127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of thyroid hormone analogs on lipid metabolism and thermogenesis.
    Ribeiro MO
    Thyroid; 2008 Feb; 18(2):197-203. PubMed ID: 18279020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.